Last reviewed · How we verify
Betamethasone plus calcipotriol
Betamethasone is a glucocorticoid receptor agonist, while calcipotriol is a vitamin D3 analog that acts as a retinoid X receptor agonist.
Betamethasone is a glucocorticoid receptor agonist, while calcipotriol is a vitamin D3 analog that acts as a retinoid X receptor agonist. Used for Psoriasis.
At a glance
| Generic name | Betamethasone plus calcipotriol |
|---|---|
| Sponsor | LEO Pharma |
| Drug class | Glucocorticoid receptor agonist and retinoid X receptor agonist |
| Target | Glucocorticoid receptor and retinoid X receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 2 |
Mechanism of action
Betamethasone and calcipotriol work synergistically to reduce inflammation and modulate the immune response in the treatment of psoriasis.
Approved indications
- Psoriasis
Common side effects
- Skin burning sensation
- Skin irritation
- Headache
Key clinical trials
- A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects (PHASE3)
- Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study (PHASE4)
- Efficacy and Safety of Xamiol® Gel Compared to Calcipotriol Scalp Solution in Patients With Scalp Psoriasis (PHASE3)
- A Psoriasis Plaque Test With LEO 29102 Cream and Its Combination Products (PHASE2)
- LEO 90105 Ointment in Japanese Subjects With Psoriasis (PHASE3)
- Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris (PHASE2)
- The Pharmacokinetics of LEO 90105 (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Extensive Psoriasis Vulgaris (PHASE1, PHASE2)
- Safety and Efficacy of LEO 80185 Gel in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Betamethasone plus calcipotriol CI brief — competitive landscape report
- Betamethasone plus calcipotriol updates RSS · CI watch RSS
- LEO Pharma portfolio CI